Table 3 Clinical and pathological characteristics associated with high tumor PD-L1 positivity in mismatch repair intact grade 2 endometrial endometrioid adenocarcinoma
Variable | Tumor PD-L1 negative (69/132; 52%) | Tumor PD-L1 high positive (21/132; 16%) | p-Value |
|---|---|---|---|
Age in years | |||
Mean (SD) | 59 (12) | 56 (12) | 0.260 |
Median (minimum–maximum) | 60 (27–82) | 59 (30–77) | |
Tumor size (mm) | |||
Mean (SD) | 43 (26) | 35 (17) | 0.355 |
Median (minimum–maximum) | 35 (13–127) | 31(12–75) | |
Tumor stage, n (%) | |||
I or II | 66 (96) | 18 (86) | 0.735 |
III or IV | 3 (4) | 3 (14) | |
Any myometrial invasion, n (%) | |||
Yes | 44 (64) | 18 (86) | 0.065 |
No | 25 (36) | 3 (14) | |
Myometrial invasion present and ≥50%, n (%) | |||
Yes | 7 (16) | 8 (44) | 0.017 |
No | 37 (84) | 10 (56) | |
Not applicable (no myometrial invasion) | 25 | 3 | |
LVSI, n (%) | |||
Yes | 8 (12) | 8 (38) | 0.005 |
No | 61 (88) | 13 (62) | |
Metastasis to pelvic lymph nodes, n (%) | |||
Yes | 2 (5) | 3 (18) | 0.165 |
No | 36 (95) | 14 (82) | |
Metastasis to para-aortic lymph nodes, n (%) | |||
Yes | 0 | 2 (18) | 0.146 |
No | 17 (100) | 9 (82) | |
PTEN IHC, n (%) | |||
Positive | 42 (61) | 8 (38) | 0.148 |
Heterogeneous | 2 (3) | 1 (5) | |
Negative | 25 (36) | 12 (57) | |
CD3 (mean cells/mm2, SD) | |||
Overall | 800 (470) | 1174 (724) | 0.014 |
Hotspot | 1287 (688) | 1963 (895) | 0.001 |
Periphery | 729 (436) | 1214 (749) | 0.002 |
Center | 811 (516) | 1134 (766) | 0.066 |
CD8 (mean cells/mm2, SD) | |||
Overall | 398 (293) | 804 (755) | 0.017 |
Hotspot | 652 (441) | 1233 (859) | 0.001 |
Periphery | 383 (275) | 882 (782) | 0.003 |
Center | 379 (319) | 720 (782) | 0.073 |
CD68 (mean cells/mm2, SD) | |||
Overall | 176 (158) | 170 (106) | 0.650 |
Hotspot | 286 (241) | 287 (159) | 0.499 |
Periphery | 157 (152) | 171 (109) | 0.231 |
Center | 193 (183) | 170 (118) | 0.963 |
